Future perspectives in the treatment of type 2 diabetes;Zukunftsperspektiven in der therapie des typ-2-diabetes

Wiener Klinische Wochenschrift

Volumn 116, Issue 7-8, 2004, Pages 213-214

  Keller, Ulrich ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cardiovascular risk factors; Diabetes mellitus type II; Obesity; Prevention

Indexed keywords

EDITORIAL; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT PLANNING;

EID: 2642534562     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03041049     Document Type: Editorial

References (12)

1. Zimmet P, Shaw J, Alberti KG (2003) Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 20: 693-702 (Review)
2. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403
3. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350
4. Schernthaner G (2003) Fortschritte in der Prävention des Typ-2-Diabetes. Wien Klin Wochenschr 115: 745-757
5. UK Prospective Diabetes Study (UKPDS) Group (1999) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (9131): 837-853. Erratum in: Lancet 354 (9178): 602
6. UK Prospective Diabetes Study (UKPDS) Group (1999) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (9131): 837-853. Erratum in: Lancet 354 (9178): 602
7. Stingl H, Roden M (2004) Zukünftige Angriffspunkte für die Therapie des Typ-2-Diabetes. Wien Klin Wochenschr 116: 217-229
8. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664-671
9. American Diabetes Association (2004) Standards of medical care in diabetes. Diabetes Care 27 [Suppl 1]: S15-35
10. Arbeitsgruppe Schweiz (2000) Gesellschaft für Endokrinologie und Diabetologie. Schweiz Ärztezeitung 81: 1403-1406
11. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393
12. Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291: 335-342